Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus

Endocrine Journal

Volumn 59, Issue 4, 2012, Pages 353-363

  Kamoi, Kyuzi ^a,d   Shinozaki, You ^a,b   Furukawa, Kazuo ^a,b   Sasaki, Hideo ^c  

^a NAGAOKA RED CROSS HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Niigata Medical Center   (Japan)

^d UNIVERSITY OF NIIGATA PREFECTURE   (Japan)

Author keywords

Body mass index (BMI); Diabetes mellitus (DM); Incretin; Test meal; Total GIP

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SECRETIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; TEST MEAL;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD;

EID: 84860621679     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0245     Document Type: Article

References (33)

1. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596.
2. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706-2713.
3. Skrha J, Hilgertová J, Jarolímková M, Kunešová M, Hill M (2010) Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and Type 2 diabetic patients. Physiol Res 59:749-755.
4. Lee S, Yabe D, Nohtomi K, Takada M, Morita R, Seino Y, Hirano T (2010) Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 57:119-126.
5. Kozawa J, Okita K, Imagawa A, Iwahashi H, Holst JJ, Yamagata K, Shimomura I (2010) Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun 393:410-413.
6. Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, Hishizawa M, Kurose T, Deacon CF, Holst JJ, Hirano T, Inagaki N, Seino Y (2010) Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of Type 2 diabetes and healthy controls. J Diabetes Invest 1: 56-59.
7. Yabe D, Watanabe K, Sugawara K, Kuwata H, Kitamoto Y, Sugizaki K, Fujiwara S, Hishizawa M, Hyo T, Kuwabara K, Yokota K, Iwasaki M, Kitatani N, Kurose T, Inagaki N, Seino Y (2012) Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Invest 3:70-79.
8. Yamada Y, Fukuda K, Fujimoto S, Hosokawa M, Tsukiyama K, Nagashima K, Fukushima M, Suzuki H, Toyoda K, Sassa M, Funakoshi S, Inagaki N, Taniguchi A, Sato TS, Matsumoto S, Tanaka K, Seino Y (2006) SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 74:222-226.
9. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M (2011) Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 58:869-877.
10. Kamoi K, Shinozaki Y, Furukawa F, Sasaki H (2011) Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues. Endocr J 58: 905-911.
11. Kamoi K, Ohara N, Ikarashi T, Shinozaki Y, Furukawa K, Sasaki H (2011) Normal response of active GLP-1 level like substances to test meal in non-obese type 2 diabetic Japanese patients with complications and receiving treatments. J Diabetes Metab 2: 147, 1000147(Epub).
12. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity (2002) New criteria for 'obesity disease' in Japan. Circ J 66: 987-992.
13. World Health Organization (1999) Definition, diagnosis and classification of diabetes and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance.
14. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 1:2-20.
15. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 1:212-228.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
17. Aoki K, Miyazaki T, Nagakura J, Orime K, Togashi Y, Terauchi Y (2010) Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide levels in healthy men. Endocr J 57:673-677.
18. Harada N, Hamasaki A, Yamane S, Muraoka A, Joo E, Fujita K, Inagaki N (2011) Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. J Diabetes Invest 2: 193-199.
19. The Japan Diabetes Society and the Japan Association for Diabetes Education and Care Committee for Standardized Incretin Measurement (2011) Guideline for Incretin Measurement. http://www.jds.or.jp/.
20. Kazakos KA, Sarafidis PA, Yovos JG (2008) The impact of diabetic autonomic neuropathy on the incretin effect. Med Sci Monit 14: CR213-220
21. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ (2001) Determinants of impaired secretion of glucagonlike peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723.
22. Krarup T, Madsbad S, Moody AJ (1988) Gastric inhibitory polypeptide in newly diagnosed ketotic type I (insulin-dependent) diabetics. Acta Med Scand 223:437-441.
23. Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 1: 8-23.
24. Yamane S, Harada N, Hamasaki A, Muraoka A, Joo E, Suzuki K, Nasteska D, Tanaka D, Ogura M, Harashima S, Inagaki N (2012) Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance. J Diabetes Invest 3:80-85.
25. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J (2011) Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 365:1597-1604.
26. Marks V (1988) GIP-the obesity hormone. In: James WPT, Parker SW, eds. Obesity, current approaches. Duphar Medical Relations. Southampton, UK: 13-20.
27. Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, Toyoda K, Naitoh R, Mizunoya W, Fushiki T, Kadowaki T, Seino Y (2005) Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 335: 937-942.
28. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742.
29. McIntosh CH, Widenmaier S, Kim SJ (2009) Glucosedependent insulinotropic polypeptide (Gastric inhibitory polypeptide; GIP). Vitam Horm 80:409-471.
30. Paschetta E, Hvalryg M, Musso G (2011) Glucosedependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders. Obes Rev 12:813-828.
31. Parker HE, Reimann F, Gribble FM (2010) Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 12:e1(Epub).
32. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207.
33. Creutzfeldt W, Talaulicar M, Ebert R, Willms B (1980) Inhibition of gastric inhibitory polypeptide (GIP) release by insulin and glucose in juvenile diabetes. Diabetes 29:140-145.